Biography for Mark Hollmer
Mark Hollmer is a veteran life sciences journalist. Before joining FierceMarkets, he was a staff writer for "The Gray Sheet," an Elsevier Business Intelligence publication, where he wrote about medical device and diagnostics startups, and regulatory milestones for large companies in both sectors, among other topics. Previously, he spent several years as a life sciences and health care reporter at the Boston Business Journal, where he followed the biotechnology, medical devices, hospital and health insurance industries. While there, he spoke regularly about top life sciences stories during appearances on New England Cable News, and commented on the growth of the Bay State's life sciences industry as part of a special that aired on the WGBH Boston public television station. Separately, he served a stint at Brown University, promoting innovations generated by the school's life sciences researchers and medical school. Mark lives with his partner in Washington, D.C. where he enjoys the region's multiple museums, great restaurants and excellent cultural scene.
Articles by Mark Hollmer
This didn't take long. Myriad Genetics' attorneys have struck again and filed a suit this time against LabCorp, barely two days after LabCorp launched a series of predictive cancer diagnostic tests focused on BRCA mutations.
Bloomberg reported that Intuitive Surgical has issued a recall affecting more than 1,300 robot arms of its da Vinci surgical around the world because they may be producing too much friction. When that happens, the da Vinci can choke during surgery and briefly stop working before it catches up.
Tyrx won FDA clearance to expand the use of its next-generation antibacterial envelope for spinal cord neuromodulator implants. In doing so, it is staking claim to an infection control market with a product line that has few, if any, competitors.
Sweden's Getinge Group will snatch up Germany's Pulsion Medical Systems in a $189 million deal that boosts its presence in the patient monitoring med tech space.
St. Jude Medical has begun enrolling patients in a clinical trial to test whether combining peripheral nerve field stimulation and spinal cord stimulation to manage chronic low back and leg pain is more effective than spinal cord stimulation alone.
Johnson & Johnson's executives preparing for upcoming trials alleging the company's Ethicon division sold faulty vaginal mesh that harmed legions of women are already facing a bombshell accusation: patients' attorneys accuse employees of destroying or losing hundreds of thousands of vital product documents.
A number of Philips automated external defibrillators may still be duds, potentially failing to deliver the shock needed in an emergency despite a recall initiated more than a year ago intended to address the issue, the FDA cautioned.
Seeking to remain ahead of the pack of medical device companies focused on developing neurostimulation devices to treat chronic pain and other conditions, St. Jude Medical has launched a clinical trial of a next-generation device that ups the ante for rivals.
Inogen has unveiled plans for an IPO worth as much as $86.2 million, becoming one of the few medical device companies to make such a move this year.
Medtronic's new surgical training facility is open for business in Jacksonville, FL. The Memphis Business Journal reported that the $14 million, 17,000-square-foot operation will train surgeons in spinal, cranial, and ear, nose and throat procedures.